Effects of Intranasal Insulin on Cognition, Mobility Studied in Elderly
Evidence from phase 2 trial suggests positive effects on cognition and gait in elderly patients with type 2 diabetes
Neurology
Labeling for Migraine Treatment Rimegepant Updated With Lactation Data
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Elamipretide Gets Orphan Drug Status for Friedreich Ataxia
Elamipretide has been shown to improve frataxin levels in Friedreich ataxia patient-derived cells, and improve motor and cardiac function in an animal model of Friedreich ataxia.
Gene Therapy for Canavan Disease Receives Multiple FDA Designations
The gene therapy candidate is designed to deliver the ASPA gene directly to the oligodendrocyte cells in the fluid surrounding the brain and spinal cord.
Gene Therapy Candidate Gets Orphan Drug Status for Adrenomyeloneuropathy
The Company will initiate a randomized, controlled phase 1/2 trial to evaluate the efficacy and safety of SBT101 in patients with AMN in the second half of 2022.
Antiseizure Treatment Explored in Comatose Cardiac Arrest Survivors
Strategy to suppress rhythmic and periodic EEG patterns did not improve neurologic outcomes at three months
Pimavanserin sNDA Resubmitted for Alzheimer Disease Psychosis
To address the issues raised in the CRL, the Company provided additional analyses from the HARMONY and Study-019 trials.
Generic Version of Cuvposa Now Available
Glycopyrrolate Oral Solution is supplied as 1mg/5mL in a 16oz bottle.
Valbenazine Improves Chorea in Patients With Huntington Disease
The phase 3 KINECT-HD study included 128 adults 18 to 75 years of age who were diagnosed with chorea associated with HD.
Trofinetide Promising for Patients With Rett Syndrome
Trofinetide is a novel synthetic analogue of the amino-terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett syndrome.
